HTG Molecular Diagnostics (HTG Molecular Diagnostics) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2023)

View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics 3-Year Revenue Growth Rate?

HTG Molecular Diagnostics's Revenue per Share for the three months ended in Mar. 2023 was $0.47.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of HTG Molecular Diagnostics's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HTG Molecular Diagnostics's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's 3-Year Revenue Growth Rate falls into.

HTG Molecular Diagnostics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

HTG Molecular Diagnostics (OTCPK:HTGMQ) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

HTG Molecular Diagnostics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

3430 E. Global Loop, Tucson, AZ, USA, 85706

Website

https://www.htgmolecular.com

HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.

Executives

Stephen Barat	officer: Senior VP of Therapeutics	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc.	10 percent owner	1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy	director
Byron Lawson	officer: SVP/Chief Commercial Officer	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson	director, officer: President & CEO
Laurence W Lytton	10 percent owner	467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski	officer: VP of Accounting and Reporting	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans	officer: VP, Finance & Admin. & CFO	3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen	10 percent owner	HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison	director